United States Patent 11,590,088: Tapinarof Patent Scope, Claims, Expiration and Generic Risk

U.S. Patent No. 11,590,088 protects a once-daily topical treatment method for mild-to-severe plaque psoriasis using approximately 1.0% tapinarof. The independent claim is directed to clinical use and treatment response, not merely to the tapinarof molecule or cream composition. Dependent claims add the oil-in-water formulation, specified excipients, patient characteristics, disease severity, outcome measures, treatment duration, durability of response and low systemic exposure.

The patent is commercially relevant to Vtama, the tapinarof 1% cream marketed by Dermavant Sciences. The principal competitive risk is a future generic tapinarof cream that seeks approval with a Paragraph IV certification or a section viii carve-out for psoriasis-related use.

What does U.S. Patent 11,590,088 cover?

Patent 11,590,088 covers methods of treating plaque psoriasis by applying a topical composition containing about 1.0% tapinarof once daily and achieving specified clinical improvement. The patent does not claim all uses of tapinarof, all tapinarof concentrations or all topical formulations.

The broadest claim requires:

A subject with mild-to-severe plaque psoriasis.
Topical administration of a composition containing about 1.0% tapinarof.
Once-daily application to affected areas.
Improvement in Physician Global Assessment, or PGA, by two grades or improvement to a PGA score of 0 or 1.

Claim 1 is therefore a method-of-treatment claim with an efficacy limitation. A competing product may face infringement risk even if its formulation differs from Vtama’s formulation, provided the accused use satisfies the concentration, dosing and clinical-response limitations.

Claim architecture

Claim group	Subject matter	Commercial significance
Claim 1	Once-daily administration of about 1.0% tapinarof with specified PGA improvement	Broadest method claim
Claims 2-4	Oil-in-water emulsion and specified oil and water phase excipients	Formulation-linked treatment claims
Claim 5	Fitzpatrick skin types I-VI	Broad demographic coverage
Claims 6-8	Treatment sites, BSA of about 3%-20%, and baseline PGA of at least 2	Patient-selection limitations
Claims 9-15	PGA, PASI, itch, PSD, DLQI and SF-36 outcomes	Clinical endpoint claims
Claims 16-19	Response after 2, 4 or 8 weeks and persistence after treatment cessation	Duration and durability claims
Claim 20	Systemic exposure below the limit of detection	Pharmacokinetic limitation
Claims 21-22	Mild-to-moderate disease, BSA of about 3%-20%, baseline PGA at least 2	Narrower patient population

The supplied text uses “PAST” in claims 9 and 11. The recognized psoriasis endpoint is the Psoriasis Area and Severity Index, or PASI. The patent’s issued text should control in any claim-construction or litigation analysis.

How broad is claim 1 of patent 11,590,088?

Claim 1 is broad in formulation terms but narrow in clinical-use terms. It does not expressly require the excipient system recited in claims 3 and 4. It also does not require a particular branded product, container, manufacturing process or chemical form of tapinarof beyond the claimed topical composition containing about 1.0% tapinarof.

The principal limitations are:

“about 1.0% tapinarof”
once-daily topical administration
mild-to-severe plaque psoriasis
PGA improvement by two grades or to 0 or 1

The PGA requirement creates a potentially material enforcement issue. Infringement cannot be established solely by proving that a product contains tapinarof and is labeled for psoriasis. The patent requires the claimed treatment regimen and the specified response. In practice, a patentee could rely on prescribing instructions, clinical protocols, product labeling, clinical studies and postmarketing use to establish induced infringement. Patient-by-patient proof of the outcome may be contested depending on the litigation theory and available evidence.

“About 1.0%” is also a claim-construction issue. It may cover a reasonable formulation range around 1.0%, but it does not automatically cover every concentration below or above 1.0%. The scope will depend on the patent specification, prosecution history, analytical precision and technical meaning of “about.”

What formulation is protected by claims 2 through 4?

Claims 2 through 4 protect treatment using an oil-in-water emulsion and, in the narrower claims, a specified excipient system.

Oil phase

Claim 3 identifies an oil phase comprising:

medium-chain triglycerides
propylene glycol
non-ionic emulsifying wax
diethylene glycol monoethyl ether
polyoxyl stearyl ether-2
polysorbate 80
polyoxyl stearyl ether-20
benzoic acid
butylated hydroxytoluene

Water phase

Claim 4 identifies a water phase comprising:

sodium citrate
edetate disodium
citric acid monohydrate
water

These claims provide a narrower formulation fallback to claim 1. A generic developer could attempt to avoid claims 2 through 4 by using a water-in-oil system, a non-emulsion vehicle, different solvents, different emulsifiers or a different preservative and antioxidant system. That design-around would not necessarily avoid claim 1, which does not expressly require the listed excipients.

The formulation claims are more useful against an exact or near-exact copy of Vtama than against a materially redesigned topical product.

Does the patent cover Vtama cream?

Vtama is tapinarof cream, 1%, for topical treatment of plaque psoriasis in adults and pediatric patients aged 2 years and older. The FDA-approved dosing is once daily on affected areas, generally up to 20% body surface area. The product’s approved use closely tracks the core elements of claim 1 and the patient-selection limitations in claims 7, 8, 21 and 22.[2]

The patent claims are not limited by the Vtama trademark. They are directed to the active ingredient, concentration, dosing schedule, disease, treatment response and, in narrower claims, formulation composition.

Vtama attribute	Relationship to patent 11,590,088
Tapinarof active ingredient	Expressly required
1% cream	Corresponds to “about 1.0%”
Once-daily use	Expressly required
Plaque psoriasis	Expressly required
PGA response	Expressly required in claim 1
Oil-in-water emulsion	Relevant to claim 2
Specific excipients	Relevant to claims 3 and 4
Up to approximately 20% BSA	Consistent with claims 7, 10, 21 and 22
Topical, low systemic exposure	Relevant to claim 20

When does patent 11,590,088 expire?

The patent family claims priority to an earlier tapinarof development program, and the relevant U.S. patent term is generally measured from the applicable nonprovisional filing date rather than the grant date. The expected base term is in the mid-2030s, subject to patent-term adjustment and any legally available extension.

The most commercially relevant date is the expiration date recorded in the USPTO and FDA Orange Book records, not the February 2023 grant date. Patent-term adjustment can move the effective expiration beyond the ordinary 20-year term. A patent-term extension based on regulatory review is a separate issue and must be confirmed from the official term record.

Exclusivity timeline

Event	Date or status
Tapinarof U.S. development and patent-family filings	Mid-2010s
Vtama FDA approval for plaque psoriasis	May 2022
Patent 11,590,088 issued	February 28, 2023
FDA pediatric exclusivity	Product-specific and dependent on FDA exclusivity records
Expected patent protection	Mid-2030s, subject to PTA and official expiration data
Generic approval before listed patents expire	Possible only through a successful challenge, non-infringing carve-out or settlement structure

FDA regulatory exclusivity and patent exclusivity are separate. A generic applicant may be blocked by a listed patent after regulatory exclusivity ends, while a patent challenge can create litigation and a potential 30-month stay under the Hatch-Waxman framework.[3]

Is patent 11,590,088 listed in the Orange Book?

The commercial relevance of patent 11,590,088 depends in part on whether it is listed for the approved Vtama drug product in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.

Orange Book listing gives the patent holder a mechanism to receive notice of a Paragraph IV certification and, if suit is filed within the statutory period, obtain a potential 30-month stay of ANDA approval. Listing does not establish that every claim is valid or infringed. It does create a procedural barrier to generic approval.

The relevant Orange Book analysis should distinguish:

drug substance patents
drug product or formulation patents
method-of-use patents
patents that may be listed but are subject to a section viii carve-out
unlisted patents that remain enforceable but do not trigger the same ANDA stay mechanism

Vtama’s Orange Book position should be assessed against the current FDA patent listing, including patent numbers, use codes and expiration dates. The patent’s method-of-use character makes the use code and the proposed generic label particularly important.

What Paragraph IV challenges could target this patent?

A generic applicant seeking approval for tapinarof cream could certify under Paragraph IV that the patent is invalid, unenforceable or will not be infringed. The most likely challenge themes are:

Lack of written description or enablement

The applicant could argue that the patent does not adequately support the full range of:

mild-to-severe plaque psoriasis
all Fitzpatrick skin types
all listed treatment sites
all claimed clinical outcomes
all compositions containing about 1.0% tapinarof
systemic exposure below the limit of detection

The breadth of claim 1 relative to the more detailed clinical and formulation disclosure would be central to this defense.

Obviousness

An obviousness challenge could combine:

known aryl hydrocarbon receptor agonist activity of tapinarof
earlier topical psoriasis studies
known 1% topical dosing
conventional oil-in-water emulsion technology
routine psoriasis endpoints such as PGA and PASI

The patentee would likely rely on clinical efficacy, tolerability, low systemic exposure, durable response and formulation performance as evidence of unexpected results. The strength of that defense would depend on the prior art available before the relevant priority date.

Indefiniteness

Potential indefiniteness issues include:

the meaning of “about 1.0%”
the scope of “below the limit of detection”
the meaning of “effective”
the measurement and timing of PGA improvement
the requirement that improvement be attributable to the claimed administration

The numerical and clinical terms are common in pharmaceutical patents but can still generate dispute where the specification does not establish clear boundaries.

Noninfringement through label design

A generic applicant could seek to omit or carve out the patented method from its label under section viii. That strategy would be difficult if the approved generic labeling necessarily directs once-daily use of 1% tapinarof for plaque psoriasis. It would be more plausible if the patent use code were narrower than the full FDA-approved indication or if the generic pursued a materially different indication.

What litigation and settlement risks affect the patent?

An ANDA Paragraph IV notice concerning patent 11,590,088 could lead to district-court litigation under 35 U.S.C. §271(e)(2). The litigation would likely address this patent together with other Vtama patents covering the active formulation or methods of use.

Potential outcomes include:

Outcome	Effect on generic entry
Patent upheld and infringed	Entry generally delayed until expiration or settlement date
Patent invalidated	Earlier approval and potential launch
Noninfringement judgment	Approval may proceed, subject to other patents
Section viii carve-out accepted	Generic approval for non-patented uses
Settlement with licensed entry	Entry date depends on negotiated terms
Authorized generic or commercial license	Earlier competition may occur without full invalidation

No settlement date, licensed-entry date or final judgment should be inferred from the patent grant alone. A complete litigation conclusion requires the relevant district-court docket, Federal Circuit decisions, FDA correspondence and any confidential or redacted settlement filings.

How strong is the patent estate for Vtama?

The estate is strongest where the generic product closely copies the approved 1% cream and uses the same once-daily psoriasis labeling. The estate is weaker against a product that:

uses a different concentration outside the construction of “about 1.0%”
pursues a non-psoriasis indication
uses a different vehicle
avoids the listed excipients
obtains a label that omits the claimed treatment method
challenges the clinical-response limitations as indefinite or unsupported

Patent-strength assessment

Issue	Relative strength
Active ingredient and 1% topical use	High commercial relevance
Once-daily psoriasis treatment	High if Orange Book listed with a matching use code
Exact excipient system	Moderate, because design-around may be feasible
PGA response limitation	Mixed; commercially relevant but proof-intensive
Low systemic exposure limitation	Mixed; analytical-method and detection-limit disputes possible
Broad skin-type coverage	Moderate
Durable response after treatment cessation	Narrower and more evidence-dependent
Manufacturing protection	Not established by the supplied claims

The supplied claims do not cover tapinarof manufacturing, crystallization, purification, scale-up, packaging or device technology. Those barriers, if present, must be found in separate patent families.

What generic launch scenarios exist?

Three scenarios are commercially credible.

Early launch after successful challenge

A generic applicant could obtain an early launch date by invalidating or avoiding the listed patents. This would create rapid price pressure in the topical psoriasis market.

Delayed launch after settlement

The applicant could agree to a negotiated entry date before patent expiration. The settlement may include a license, supply arrangement, authorized generic rights or restrictions on the generic label.

Launch after patent expiration

If the patents remain enforceable and no settlement permits earlier entry, a generic launch would likely be delayed until the applicable listed patents expire, subject to patent-term adjustment and regulatory exclusivity.

The principal revenue exposure is concentrated in the period between the end of FDA exclusivity and the first legally permitted generic entry. Exact revenue impact depends on Vtama sales, payer coverage, generic launch count, substitution rates and the number of enforceable patents remaining at that time.

How does patent 11,590,088 compare with formulation patents?

Patent 11,590,088 is primarily a treatment-method patent. Formulation patents generally offer a different infringement theory because they focus on the composition itself rather than the clinical use.

Patent type	Main protected subject matter	Generic design-around
Method-of-use	Treating psoriasis with 1% tapinarof once daily	Label carve-out, different indication or challenge
Formulation	Cream composition and excipient system	Alter vehicle or excipient concentrations
Drug substance	Tapinarof compound or solid form	Difficult if the active ingredient is required
Manufacturing	Process steps and controls	Alternative process
Device or packaging	Delivery system	Alternative container or applicator

A layered estate combining formulation and method claims is more difficult to avoid than a single method patent. Patent 11,590,088 alone does not establish the full scope of the Vtama estate.

Key Takeaways

U.S. Patent 11,590,088 claims once-daily topical treatment of plaque psoriasis with approximately 1.0% tapinarof.
Claim 1 requires a specified PGA response, making it broader in formulation terms but narrower in clinical-use terms.
Claims 2 through 4 add an oil-in-water emulsion and a detailed excipient system.
Claims 7, 8, 21 and 22 align closely with the clinical population and BSA range in the Vtama label.
Claims 16 through 19 protect response timing and persistence after treatment cessation.
Claim 20 targets low or undetectable systemic exposure.
Expected protection extends into the mid-2030s, subject to official patent-term adjustment and FDA listing data.
Generic risk will depend on Orange Book listing, the use code, Paragraph IV certifications, label carve-outs and the treatment of related Vtama patents.
The strongest infringement case is against a generic 1% tapinarof cream carrying a once-daily plaque-psoriasis label.
The patent does not, based on the supplied claims, protect tapinarof manufacturing or every possible topical formulation.

FAQs About U.S. Patent 11,590,088

Does patent 11,590,088 cover tapinarof for atopic dermatitis?

No. The supplied claims are directed to treatment of plaque psoriasis. A separate patent or claim set would be needed to assess tapinarof treatment for atopic dermatitis.

Can a generic use a tapinarof formulation different from Vtama?

Potentially. A different formulation may avoid claims 2 through 4, but it could still implicate claim 1 if it contains about 1.0% tapinarof and is labeled for once-daily plaque-psoriasis treatment.

Does FDA approval prove infringement of patent 11,590,088?

No. FDA approval and patent infringement are separate issues. Approval may create an infringement dispute if the proposed label induces use that falls within the patent claims.

What does a section viii statement mean for this patent?

A section viii statement seeks approval for uses that do not correspond to the patented method. Its viability depends on the Orange Book use code and whether the remaining generic label still encourages the claimed psoriasis treatment.

Is tapinarof a biologic subject to biosimilar competition?

No. Tapinarof is a small-molecule topical active ingredient. Competition would generally proceed through the ANDA generic-drug pathway, not the biosimilar pathway under the Public Health Service Act.

References

United States Patent and Trademark Office. (2023). U.S. Patent No. 11,590,088: Methods of treating plaque psoriasis with tapinarof.
U.S. Food and Drug Administration. (2022). Vtama (tapinarof) cream, 1% prescribing information. Dermavant Sciences Ltd.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations, patent and exclusivity information.
U.S. Food and Drug Administration. (2024). ANDA submissions: Amendments and requests for final approval to tentatively approved ANDAs.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes	11,590,088	⤷ Start Trial				TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 11,590,088

Which drugs does patent 11,590,088 protect, and when does it expire?

Summary for Patent: 11,590,088